Positive effects of soy isoflavone food on survival of breast cancer patients in China.

Department of General Surgery, The Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China.
Asian Pacific journal of cancer prevention: APJCP (Impact Factor: 1.5). 02/2012; 13(2):479-82. DOI: 10.7314/APJCP.2012.13.2.479
Source: PubMed

ABSTRACT Soy foods are the major source of isoflavones, which are believed to play important roles in genesis of breast cancer and its progression. We here conducted a prospective study to evaluate the association of soy isoflavone food consumption with breast cancer prognosis.
A prospective study was performed from January 2004 and January 2006 in China. Trained interviewers conducted face-to-face interviews using a structured questionnaire to collect information on dietary habits and potential confounding factors. The relative risk [hazard ratio (HR)] and 95% CI were calculated from the Cox regression model for all significant predictors from cancer diagnosis to the endpoint of the study (event).
After a median follow up of 52.1 months (range, 9-60 months), a total of 79 breast cancer related deaths were recorded in our study, risk being inversely associated with a high intake of soy isoflavone. With an average intake of soy isoflavone above 17.3 mg/day, the mortality of breast cancer can be reduced by about 38-36%. We also found the decreased breast cancer death with high soy protein intake, with a HR (95% CI) of 0.71 (0.52-0.98). Stratified analysis with reference to the ER status, further demonstrated a better prognosis of ER positive breast cancer with a high intake of soy isoflavone (HR 0.59, 0.40-0.93).
Our study shows the soy food intake is associated with longer survival and low recurrence among breast cancer patients. A cohort study with a larger sample size and long term follow-up is now needed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this meta-analysis was to assess if the -634G/C polymorphism represents a predisposition factor for the risk of breast cancer. We included eight published case-control studies, in which a total of 6,175 cancer cases and 6,421 cancer-free controls were included. Pooled ORs and 95 % CIs were calculated by the fixed effects model to evaluate the association of the -634G/C polymorphism and breast cancer risk. When all studies were pooled, we did not find statistical evidence of any significant association with overall breast cancer risk (ORBB vs. bb = 1.00, 95 % CI = 0.93-1.07, P = 0.999; ORBB + Bb vs. bb = 1.00, 95 % CI = 0.95-1.05, P = 0.999; ORBB vs. Bb + bb = 1.03, 95 % CI = 0.96-1.09, P = 0.984; ORallele B vs. allele b = 1.01, 95 % CI = 0.97-1.05, P = 0.998; ORBb vs. bb = 0.99, 95 % CI = 0.92-1.06, P = 0.992). In further stratified analyses by ethnicity and control source, no significant association was revealed. This study suggests that the -634G/C polymorphism does not appear to represent a risk factor for breast cancer.
    Tumor Biology 05/2014; · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to evaluate the association of seven VEGF promoter polymorphisms with breast cancer risk in Punjabi population from North West India. We screened DNA samples of 102 sporadic breast cancer patients and 102 unrelated healthy, gender, and age-matched individuals for seven VEGF promoter polymorphisms [-417C/T (rs833062), -172C/A (rs59260042), -165C/T (rs79469752), -160C/T, -152G/A (rs13207351), -141A/C (rs28357093) and -116G/A (rs1570360)] by direct sequencing. The frequency of GG, GA, and AA genotype of -152G/A polymorphism was 26.47 vs 38.34 %, 46.08 vs 51.96 %, and 27.45 vs 9.80 %, in patients and controls, respectively. VEGF -152 AA genotype was significantly associated with increased risk for breast cancer (OR = 4.04, 95 %CI, 1.69-9.68, p = 0.001; recessive model OR = 3.48, 95 %CI, 1.59-7.63, p = 0.001). For VEGF -116G/A polymorphism, G and A allele frequencies were 65.2 vs 76.47 % and 34.8 vs 23.53 % in patients and controls, respectively. Individuals having -116AA genotype (OR = 3.40; 95 %CI, 1.24-9.37; p = 0.014) and A allele (OR = 1.73; 95 %CI, 1.12-2.67; p = 0.012) were associated with increased risk for breast cancer. VEGF -165C/T and -141A/C polymorphisms were associated with reduced risk for breast cancer. There was significantly decreased frequency of CT genotype (4.90 vs 18.63 %; p = 0.002) and T allele (2.45 vs 9.31 %; p = 0.003) of -165C/T polymorphism among breast cancer patients as compared to controls. VEGF -141A and C allele frequency were 96.57 vs 91.18 % and 3.43 vs 8.82 % in patients and controls, respectively. Significant reduced risk for breast cancer was observed with AC genotype (OR = 0.34, 95 %CI, 0.14-0.86; p = 0.019) and C allele (OR = 0.37; 95 %CI, 0.15-0.89; p = 0.023) of -141A/C polymorphism. We did not observe association of VEGF -417T/C, -172C/A, -160C/T polymorphisms with breast cancer risk in the studied subjects (p > 0.05). The VEGF -152G/A and -116G/A polymorphisms were found to be significantly associated with increased risk for breast cancer while -165C/T and -141A/C polymorphisms were found to be associated with decreased risk for breast cancer in Punjabi population from North West India.
    Tumor Biology 08/2014; 35(11). · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over the past 2 decades, soy foods have been the subject of a vast amount of research, primarily because they are uniquely rich sources of isoflavones. Isoflavones are classified as both phytoestrogens and selective estrogen receptor modulators. The phytoestrogenic effects of isoflavones have led some to view soy foods and isoflavone supplements as alternatives to conventional hormone therapy. However, clinical research shows that isoflavones and estrogen exert differing effects on a variety of health outcomes. Nevertheless, there is substantial evidence that soy foods have the potential to address several conditions and diseases associated with the menopausal transition. For example, data suggest that soy foods can potentially reduce ischemic heart disease through multiple mechanisms. Soy protein directly lowers blood low-density lipoprotein-cholesterol concentrations, and the soybean is low in saturated fat and a source of both essential fatty acids, the omega-6 fatty acid, linoleic acid and the omega-3 fatty acid, alpha-linolenic acid. In addition, isoflavones improve endothelial function and possibly slow the progression of subclinical atherosclerosis. Also, isoflavone supplements consistently alleviate menopausal hot flashes provided they contain sufficient amounts of the predominant soybean isoflavone genistein. In contrast, the evidence that isoflavones reduce bone loss in postmenopausal women is unimpressive. Whether adult soy food intake reduces breast cancer risk is unclear. Considerable evidence suggests that for soy to reduce risk, consumption during childhood and/or adolescence is required. Although concerns have been raised that soy food consumption may be harmful to breast cancer patients, an analysis in 9514 breast cancer survivors who were followed for 7.4 y found that higher postdiagnosis soy intake was associated with a significant 25% reduction in tumor recurrence. In summary, the clinical and epidemiologic data indicate that adding soy foods to the diet can contribute to the health of postmenopausal women.
    American Journal of Clinical Nutrition 06/2014; 100(Supplement_1). · 6.92 Impact Factor


Available from